Clinical trial

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis…

NCT00077623 · Hoffmann-La Roche, Industry · Completed

Key facts

NCT number NCT00077623
Title A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
Official title A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis
Lead sponsor Hoffmann-La Roche, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Anemia
Intervention type Drug
Interventions epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta (Mircera)
Enrollment 572
Start date Mar 1, 2004
Primary completion Sep 1, 2005
Completion Sep 1, 2005
First posted Feb 13, 2004
Last update posted May 25, 2016
Countries Belgium, Brazil, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Mexico, New Zealand, Panama and 9 more

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies